Global Preterm Birth Prevention and Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Preterm Birth Prevention and Treatment Market Research Report 2024
Preterm birth is among the prevalent public health concerns all over the world and has become the primary cause of mortality in children aging below 5 years. To curb the alarming situation, governments including, the Food and Drug Administration (FDA), are showing immediacy in approving drugs for preterm birth prevention and management.
According to Mr Accuracy reports new survey, global Preterm Birth Prevention and Treatment market is projected to reach US$ 1760.1 million in 2029, increasing from US$ 1412 million in 2022, with the CAGR of 3.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Preterm Birth Prevention and Treatment market research.
The preterm birth prevention and management market is driven by the increasing awareness about the adverse effects of preterm birth on neonatal health and the growing emphasis on maternal and child healthcare. Preterm birth, defined as delivery before 37 weeks of pregnancy, poses significant risks to both the baby and the mother. Advances in medical research and technology have led to the development of various interventions and treatments to prevent and manage preterm birth, such as progesterone supplements, cervical cerclage, and improved prenatal care. Additionally, rising healthcare expenditure and government initiatives aimed at reducing preterm birth rates are contributing to the market's growth. However, challenges include the complex and multifactorial nature of preterm birth, making it difficult to predict and prevent in all cases. The effectiveness of interventions can vary depending on individual patient factors, leading to a need for personalized treatment approaches. Furthermore, access to quality healthcare and specialized facilities can be a challenge in some regions, impacting the implementation of effective preterm birth prevention and management strategies. As healthcare systems continue to evolve and research in this field progresses, the preterm birth prevention and management market is expected to witness advancements that improve maternal and neonatal outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Preterm Birth Prevention and Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AMAG Pharmaceuticals
Ferring Pharmaceutical
Teva
Allergan
AbbVie
Aurobindo Pharma
Bayer
Viatris
Pfizer
Merck & Co
Novartis
Sanofi
Segment by Type
Progesterone Therapy
Corticosteroid Therapy
Tocolytics Therapy
Antihypertensive Therapy
Magnesium Sulfate Therapy
Other
Hospital
Drugs Stores
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Preterm Birth Prevention and Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Preterm Birth Prevention and Treatment market is projected to reach US$ 1760.1 million in 2029, increasing from US$ 1412 million in 2022, with the CAGR of 3.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Preterm Birth Prevention and Treatment market research.
The preterm birth prevention and management market is driven by the increasing awareness about the adverse effects of preterm birth on neonatal health and the growing emphasis on maternal and child healthcare. Preterm birth, defined as delivery before 37 weeks of pregnancy, poses significant risks to both the baby and the mother. Advances in medical research and technology have led to the development of various interventions and treatments to prevent and manage preterm birth, such as progesterone supplements, cervical cerclage, and improved prenatal care. Additionally, rising healthcare expenditure and government initiatives aimed at reducing preterm birth rates are contributing to the market's growth. However, challenges include the complex and multifactorial nature of preterm birth, making it difficult to predict and prevent in all cases. The effectiveness of interventions can vary depending on individual patient factors, leading to a need for personalized treatment approaches. Furthermore, access to quality healthcare and specialized facilities can be a challenge in some regions, impacting the implementation of effective preterm birth prevention and management strategies. As healthcare systems continue to evolve and research in this field progresses, the preterm birth prevention and management market is expected to witness advancements that improve maternal and neonatal outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Preterm Birth Prevention and Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AMAG Pharmaceuticals
Ferring Pharmaceutical
Teva
Allergan
AbbVie
Aurobindo Pharma
Bayer
Viatris
Pfizer
Merck & Co
Novartis
Sanofi
Segment by Type
Progesterone Therapy
Corticosteroid Therapy
Tocolytics Therapy
Antihypertensive Therapy
Magnesium Sulfate Therapy
Other
Segment by Application
Hospital
Drugs Stores
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Preterm Birth Prevention and Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices